Physician profile
Amit Ahuja
NPI 1528061959
$3,532.76
in general payments reported to CMS, 2019-2025
27 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $648 · 2021: $1,005 · 2022: $319 · 2023: $125 · 2024: $193 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $657.95 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $615.44 | 2019-2021 | |
| Pfizer INC. | $507.52 | 2019-2021 | |
| Janssen Biotech, INC. | $252.77 | 2019-2022 | |
| Abbvie INC. | $174.47 | 2020-2024 | |
| Ferring Pharmaceuticals INC. | $140.91 | 2019-2024 | Rebyota |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $120.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $107.15 | 2025 | Spravato |
| Penumbra, INC. | $107.04 | 2022 | |
| Bard Peripheral Vascular, INC. | $94.83 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $94.13 | 2019-2021 | |
| Ethicon US, LLC | $81.44 | 2021 | |
| Allergan, INC. | $51.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $37.69 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $35.72 | 2019 | |
| Braintree Laboratories, INC. | $30.10 | 2020 | |
| Redhill Biopharma INC. | $29.73 | 2021 | |
| Ardelyx, INC. | $25.92 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $23.56 | 2019 | |
| Medtronic Vascular, INC. | $19.87 | 2020 | |
| Microvention, INC. | $17.90 | 2022 | |
| Ucb, INC. | $16.07 | 2019 | |
| Shionogi INC | $14.24 | 2019 | |
| Evoke Pharma, INC. | $14.16 | 2021 | |
| Intercept Pharmaceuticals, INC. | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.